Are frailty scores being used in clinical trials? How?

Are frailty scores being used in clinical trials? How? At present, the recommendations from many large societies, primarily in Europe, has been that we use or incorporate frailty indices into all adult patients with myeloma who are about to start a myeloma therapy. In reality, what is happening is that the uptake of frailty indices has been a little bit slower, and so right now the most place, the place where you'll see this often used is in the research setting. So if I'm in my clinical practice, I generally would use the Revised Myeloma Comorbidity Index or the International Myeloma Working Group frailty score, which is the most commonly used, and we can talk a little bit about what that is, and I use that on all of my patients with newly diagnosed multiple myeloma. And then I tend to track that over time, so I want to see as these patients go through their treatments, how does their frailty score or frailty index actually change? Because then that tells me or gives me an idea that with this patient's treatment, they may be tolerating it well or they may be tolerating it poorly, and they may be an indication that I actually need to make some changes.